Related Experiment Videos
New treatments for multiple myeloma
Paul G Richardson1, Robert Schlossman, Teru Hideshima
1Harvard Medical School, Boston, Massachusetts, USA. Paul_Richardson@dfci.harvard.edu
Oncology (Williston Park, N.Y.)
|March 2, 2006
Summary
New treatments for multiple myeloma, including bortezomib (Velcade), offer improved survival for patients. Ongoing research into novel agents promises further positive outcomes for this hematologic malignancy.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma is a significant cause of cancer death, with traditional therapies offering limited survival benefits.
- Median survival for multiple myeloma patients has historically been 3-5 years despite various treatments.
- Hematologic malignancies like multiple myeloma require continuous development of effective therapeutic strategies.
Purpose of the Study:
- To review recent advancements in multiple myeloma treatment.
- To highlight the impact of novel therapeutic agents on patient survival.
- To discuss the ongoing investigation of new and combination therapies for multiple myeloma.
Main Methods:
- Review of current and emerging treatments for multiple myeloma.
- Analysis of the efficacy of novel agents like bortezomib, thalidomide, and lenalidomide.
- Examination of treatment strategies including induction therapy and management of relapsed disease.
Main Results:
- Bortezomib (Velcade) has been approved for patients with relapsed multiple myeloma.
- Novel agents like thalidomide (Thalomid) and lenalidomide (Revlimid) show promise.
- Combination therapies and targeted treatments are under investigation for improved outcomes.
Conclusions:
- Recent therapeutic advances offer a positive outlook for multiple myeloma patients.
- Further research into novel agents and combination regimens is crucial.
- The evolving treatment landscape is expected to enhance patient survival and quality of life.